212 related articles for article (PubMed ID: 33050937)
21. Thyroid carcinoma in patients with Graves' disease: an institutional experience.
Wei S; Baloch ZW; LiVolsi VA
Endocr Pathol; 2015 Mar; 26(1):48-53. PubMed ID: 25332114
[TBL] [Abstract][Full Text] [Related]
22. Lobectomy Is Feasible for 1-4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence.
Song E; Han M; Oh HS; Kim WW; Jeon MJ; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Hong SJ; Sung TY; Kim WG
Thyroid; 2019 Jan; 29(1):64-70. PubMed ID: 30375260
[TBL] [Abstract][Full Text] [Related]
23. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
24. Risk Factors for Recurrence After Treatment of N1b Papillary Thyroid Carcinoma.
Lee SH; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg; 2019 May; 269(5):966-971. PubMed ID: 29462007
[TBL] [Abstract][Full Text] [Related]
25. Investigating the prevalence of risk factors of papillary thyroid carcinoma recurrence and disease-free survival after thyroidectomy and central neck dissection in Iranian patients.
Arianpoor A; Asadi M; Amini E; Ziaeemehr A; Ahmadi Simab S; Zakavi SR
Acta Chir Belg; 2020 Jun; 120(3):173-178. PubMed ID: 31237189
[No Abstract] [Full Text] [Related]
26. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer.
Hales IB; McElduff A; Crummer P; Clifton-Bligh P; Delbridge L; Hoschl R; Poole A; Reeve TS; Wilmshurst E; Wiseman J
J Clin Endocrinol Metab; 1992 Sep; 75(3):886-9. PubMed ID: 1517381
[TBL] [Abstract][Full Text] [Related]
27. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
28. Should Level V Be Routinely Dissected in N1b Papillary Thyroid Carcinoma?
Kim SK; Park I; Hur N; Lee JH; Choe JH; Kim JH; Kim JS
Thyroid; 2017 Feb; 27(2):253-260. PubMed ID: 27762727
[TBL] [Abstract][Full Text] [Related]
29. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
Wu Y; Li J; Wu X; Dai L
Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
[TBL] [Abstract][Full Text] [Related]
30. Multifocality Is not an Independent Prognostic Factor in Papillary Thyroid Cancer: A Propensity Score-Matching Analysis.
Geron Y; Benbassat C; Shteinshneider M; Or K; Markus E; Hirsch D; Levy S; Ziv-Baran T; Muallem-Kalmovich L
Thyroid; 2019 Apr; 29(4):513-522. PubMed ID: 30799769
[TBL] [Abstract][Full Text] [Related]
31. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
[TBL] [Abstract][Full Text] [Related]
32. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of surgical strategy for pediatric papillary thyroid carcinoma with low-intermediate risk].
Zhao L; Li H; He YY; Wang K; Wang J; Yan DG; Ni S; Zhu YM; Liu SY
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Dec; 57(12):1396-1402. PubMed ID: 36707942
[No Abstract] [Full Text] [Related]
34. Comparison of clinicopathological features and prognosis of papillary thyroid carcinoma and microcarcinoma: A population-based propensity score matching analysis.
Qian B; Hu L; Zhang S; Zhu J; Mei L; Huang T; Qu X
Front Endocrinol (Lausanne); 2022; 13():944758. PubMed ID: 35992148
[TBL] [Abstract][Full Text] [Related]
35. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
36. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Lateral Neck Recurrence of N0/N1a Papillary Thyroid Cancer.
Kim Y; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2017 Nov; 24(12):3609-3616. PubMed ID: 28822118
[TBL] [Abstract][Full Text] [Related]
38. Does microscopic positive tumor margin in papillary thyroid cancer really matter?
Back K; Kim SK; Chai YJ; Kim JH; Choe JH; Kim JS
Surgery; 2019 Dec; 166(6):1160-1167. PubMed ID: 31582308
[TBL] [Abstract][Full Text] [Related]
39. Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.
Ito Y; Miyauchi A; Masuoka H; Fukushima M; Kihara M; Miya A
World J Surg; 2018 Aug; 42(8):2462-2468. PubMed ID: 29372373
[TBL] [Abstract][Full Text] [Related]
40. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
